Table 1.
Patient characteristics at baseline
| Placebo (N = 8) | Luseogliflozin | ||||
|---|---|---|---|---|---|
| 0.5 mg (N = 8) | 1 mg (N = 8) | 2.5 mg (N = 8) | 5 mg (N = 8) | ||
| Sex | |||||
| Male | 7 | 7 | 6 | 8 | 6 |
| Female | 1 | 1 | 2 | 0 | 2 |
| Age (years) | 57.3 ± 7.4 | 58.8 ± 10.1 | 59.8 ± 10.8 | 55.9 ± 8.8 | 57.6 ± 8.2 |
| Body weight (kg) | 75.96 ± 9.70 | 66.75 ± 13.61 | 72.12 ± 18.57 | 68.00 ± 7.90 | 71.80 ± 9.59 |
| BMI (kg/m2) | 26.78 ± 3.13 | 23.43 ± 3.37 | 25.94 ± 4.98 | 24.38 ± 3.35 | 26.13 ± 2.83 |
| Diabetes duration (years) | 3.4 ± 2.5 | 3.5 ± 3.9 | 5.3 ± 4.9 | 2.4 ± 1.6 | 4.4 ± 1.8 |
| HbA1c (%) | 8.51 ± 0.91 | 8.55 ± 1.02 | 8.01 ± 1.01 | 8.70 ± 1.08 | 7.99 ± 1.01 |
| FPG (mg/dL) | 166.5 ± 21.4 | 162.0 ± 29.2 | 151.3 ± 32.0 | 166.5 ± 37.9 | 150.1 ± 22.0 |
| UGE0–24h (g) | 26.3 ± 19.7 | 30.5 ± 24.7 | 17.0 ± 15.3 | 44.1 ± 29.4 | 16.2 ± 14.0 |
| eGFR (mL/min/1.73 m2) | 103.9 ± 21.4 | 84.7 ± 17.4 | 87.8 ± 13.2 | 89.3 ± 16.2 | 88.9 ± 22.4 |
Values are presented as the mean ± standard deviation
BMI body mass index, HbA1c hemoglobin A1c, FPG fasting plasma glucose, UGE 0–24h urinary glucose excretion from 0 to 24 h, eGFR estimated glomerular filtration rate